News

Semaglutide for Athletes: Weight Cutting Without Sacrificing Bone Density?
Female athletes cutting weight face bone density risks when energy deficits disrupt menstrual cycles. Semaglutide may offer appetite control without Read more...
Semaglutide Misuse and Unregulated GLP-1 Compounding Risks
NBC 5 Chicago's warning on semaglutide misuse highlights the dangers of unregulated GLP-1 compounding. This article examines the clinical evidence Read more...
Retatrutide's Triple Agonism for Obesity-Related Alcohol Use Disorder: What the VA GLP-1 Trial Means
Retatrutide's triple agonism targets GLP-1, GIP, and glucagon receptors, potentially offering superior benefits for obesity-related alcohol use disorder. A VA Read more...
Retatrutide vs. Tirzepatide: Triple Agonism and FDA Compounding Warnings
Retatrutide's triple agonism adds glucagon to GLP-1 and GIP, pushing weight loss beyond tirzepatide's dual action. But FDA warnings on compounded Read more...
Retatrutide’s Triple Agonism: Will the FDA’s Peptide Shift Unlock Compounded Access Before Full Approval?
Retatrutide’s triple agonism yields weight loss rivaling surgery, but the FDA’s peptide reclassification could open compounded access before full approval Read more...
Semaglutide GI Side Effects: A Ramadan Interruption Case
A case report links semaglutide to severe GI side effects during Ramadan fasting, forcing interruption. We explore reintroduction strategies, female-specific Read more...
Retatrutide and Tesamorelin Stack: Visceral Fat Reduction Without Muscle Loss?
Retatrutide and tesamorelin may synergistically reduce visceral fat while preserving muscle, but female-specific data is lacking. This article examines the Read more...